LQDA

The past six months saw significant volatility in Liquidia's stock, largely due to a critical patent litigation ruling. On September 30, 2026, the stock plunged approximately 57% after a U.S. District Court ruled that YUTREPIA infringed two valid claims of United Therapeutics' '327 patent, specifically impacting its PH-ILD approval. Following this, in early October 2026, multiple financial analysts downgraded Liquidia's stock and substantially cut their price targets. In August 2026, Liquidia reported Q2 2026 financial results, missing EPS estimates but showing strong revenue and net income, with YUTREPIA sales exceeding expectations, yet the stock still pulled back. In May 2026, the company reported Q1 2026 financial results, which coincided with a +25.60% positive price movement.